173 related articles for article (PubMed ID: 36306196)
21. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
22. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract][Full Text] [Related]
24. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Meyer T; Qian W; Caplin ME; Armstrong G; Lao-Sirieix SH; Hardy R; Valle JW; Talbot DC; Cunningham D; Reed N; Shaw A; Navalkissoor S; Luong TV; Corrie PG
Eur J Cancer; 2014 Mar; 50(5):902-11. PubMed ID: 24445147
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
27.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
30. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract][Full Text] [Related]
31. Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.
Soulen MC; Teitelbaum UR; Mick R; Eads J; Mondschein JI; Dagli M; van Houten D; Damjanov N; Schneider C; Cengel K; Metz DC
Cardiovasc Intervent Radiol; 2024 Jan; 47(1):60-68. PubMed ID: 38057498
[TBL] [Abstract][Full Text] [Related]
32. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Spada F; Maisonneuve P; Fumagalli C; Marconcini R; Gelsomino F; Antonuzzo L; Campana D; Puliafito I; Rossi G; Faviana P; Messerini L; Barberis M; Fazio N
Endocrine; 2021 Apr; 72(1):268-278. PubMed ID: 32700133
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
35. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
Raimondi A; Corallo S; Niger M; Antista M; Randon G; Morano F; Milione M; Kusamura S; Baratti D; Guaglio M; Cremolini C; Marmorino F; Di Bartolomeo M; Deraco M; De Braud F; Pietrantonio F
Clin Colorectal Cancer; 2019 Jun; 18(2):e179-e190. PubMed ID: 31023524
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
38. Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.
Bongiovanni A; Riva N; Calpona S; Ricci M; Gunelli E; Liverani C; La Manna F; De Vita A; Monti M; Severi S; Pieri F; Amadori E; Galassi R; Cavaliere D; Zaccaroni A; Tartaglia A; Lunedei V; Gardini A; Mercatali L; Amadori D; Ibrahim T
Onco Targets Ther; 2014; 7():1919-26. PubMed ID: 25364262
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B
Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
